| Year |
Citation |
Score |
| 2023 |
Olson KM, Devereaux AL, Chatterjee P, Saldaña-Shumaker SL, Shafer A, Plotkin A, Kandasamy R, MacKerell AD, Traynor JR, Cunningham CW. Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy. Frontiers in Pharmacology. 14: 1230053. PMID 37469877 DOI: 10.3389/fphar.2023.1230053 |
0.794 |
|
| 2022 |
Olson KM, Hillhouse TM, Burgess GE, West JL, Hallahan JE, Dripps IJ, Ladetto AG, Rice KC, Jutkiewicz EM, Traynor JR. Delta opioid receptor-mediated antidepressant-like effects of diprenorphine in mice. The Journal of Pharmacology and Experimental Therapeutics. PMID 36456196 DOI: 10.1124/jpet.122.001182 |
0.832 |
|
| 2022 |
Disney A, Olson KM, Shafer AM, Moore SC, Anand JP, Traynor JR, Husbands SM. Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose. Acs Chemical Neuroscience. PMID 36223082 DOI: 10.1021/acschemneuro.2c00464 |
0.806 |
|
| 2022 |
Olson KM, Campbell A, Alt A, Traynor JR. Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands. Acs Pharmacology & Translational Science. 5: 694-709. PMID 36110374 DOI: 10.1021/acsptsci.1c00256 |
0.783 |
|
| 2022 |
Gerak LR, Maguire DR, Cami-Kobeci G, Olson KM, Traynor JR, Husbands SM, France CP, Acevedo L, Belli B, Flynn P. OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects. Behavioural Pharmacology. 33: 377-394. PMID 35947066 DOI: 10.1097/FBP.0000000000000684 |
0.842 |
|
| 2022 |
Chan WKB, Olson KM, Wotring JW, Sexton JZ, Carlson HA, Traynor JR. In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs. Scientific Reports. 12: 5320. PMID 35351926 DOI: 10.1038/s41598-022-08320-y |
0.719 |
|
| 2021 |
Olson KM, Traynor JR, Alt A. Allosteric Modulator Leads Hiding in Plain Site: Developing Peptide and Peptidomimetics as GPCR Allosteric Modulators. Frontiers in Chemistry. 9: 671483. PMID 34692635 DOI: 10.3389/fchem.2021.671483 |
0.749 |
|
| 2021 |
Keresztes A, Olson K, Nguyen P, Lopez-Pier MA, Hecksel R, Barker NK, Liu Z, Hruby V, Konhilas J, Langlais PR, Streicher JM. Antagonism of the Mu-Delta Opioid Receptor Heterodimer Enhances Opioid Anti-Nociception by Activating Src and CaMKII Signaling. Pain. PMID 34252907 DOI: 10.1097/j.pain.0000000000002320 |
0.832 |
|
| 2021 |
Hillhouse TM, Olson K, Hallahan JE, Rysztak LG, Sears BF, Meurice C, Ostovar M, Koppenhaver PO, West J, Jutkiewicz EM, Husbands SM, Traynor JR. The Journal of Pharmacology and Experimental Therapeutics. PMID 34183434 DOI: 10.1124/jpet.121.000524 |
0.785 |
|
| 2020 |
Olson KM, Hillhouse TE, Sears BF, Rysztak L, Husband SM, Jutkiewicz EM, Traynor JR. Buprenorphine Analogs to Treat Relapse The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.06835 |
0.748 |
|
| 2019 |
Olson KM, Duron DI, Womer D, Fell R, Streicher JM. Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids. Plos One. 14: e0217371. PMID 31170174 DOI: 10.1371/Journal.Pone.0217371 |
0.842 |
|
| 2018 |
Olson KM, Keresztes A, Tashiro JK, Daconta LV, Hruby VJ, Streicher JM. Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice. Journal of Medicinal Chemistry. PMID 29939746 DOI: 10.1021/Acs.Jmedchem.8B00403 |
0.831 |
|
| 2017 |
Olson KM, Lei W, Keresztes A, LaVigne J, Streicher JM. Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain. The Yale Journal of Biology and Medicine. 90: 97-110. PMID 28356897 |
0.841 |
|
| 2015 |
Giri AK, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F, Vanderah TW, Hruby VJ. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. Journal of Medicinal Chemistry. PMID 26465170 DOI: 10.1021/Acs.Jmedchem.5B01170 |
0.8 |
|
| Show low-probability matches. |